ANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Overview - ANI Pharmaceuticals is focused on building a high-growth and profitable business in rare disease therapeutics, with three business segments [3]. Business Segments - The rare disease segment is the key focus area and the largest driver of growth for ANI Pharmaceuticals [3]. - The company has two assets in the rare disease business: Cortrophin and ILUVIEN [3]. - It is projected that the rare disease segment will account for approximately 50% of the company's revenues by 2025 [3].